Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis

被引:10
|
作者
Chys, Brecht [1 ]
Devos, Gaetan [1 ]
Everaerts, Wouter [1 ]
Albersen, Maarten [1 ]
Moris, Lisa [1 ,2 ]
Claessens, Frank [2 ]
De Meerleer, Gert [3 ]
Haustermans, Karin [3 ]
Briganti, Alberto [4 ]
Chlosta, Piotr [5 ]
Gontero, Paolo [6 ]
Graefen, Markus [7 ]
Gratzke, Christian [8 ]
Karnes, R. Jeffrey [9 ]
Kneitz, Burkhard [10 ]
Marchioro, Giansilvio [11 ]
Salas, Rafael Sanchez [12 ,13 ]
Spahn, Martin [14 ]
Tombal, Bertrand [15 ]
Van Der Poel, Henk [16 ]
Walz, Jochen [17 ]
Van Poppel, Hendrik [1 ]
Joniau, Steven [1 ]
机构
[1] Univ Hosp Leuven, Dept Dev & Regenerat, Urol, Leuven, Belgium
[2] Katholieke Univ Leuven, Lab Mol Endocrinol, Leuven, Belgium
[3] Univ Hosp Leuven, Dept Radiat Oncol, Leuven, Belgium
[4] Univ Vita Salute, Hosp San Raffaele, Dept Urol, Milan, Italy
[5] Jagiellonian Univ Med Coll, Dept Urol, Krakow, Poland
[6] Univ Turin, Dept Urol, Turin, Italy
[7] UKE GmbH, Dept Urol, Martini Klin, Hamburg, Germany
[8] Ludwig Maximilians Univ Munchen, Urolog Klin & Poliklin, Munich, Germany
[9] Mayo Clin, Dept Urol, Rochester, NY USA
[10] Univ Hosp Wurzburg, Dept Urol & Pediat Urol, Wurzburg, Germany
[11] Univ Piemonte Orientale, Dept Urol, Novara, Italy
[12] Inst Mutualiste Montsouris, Dept Urol, Paris, France
[13] Paris Descartes Univ, Paris, France
[14] Univ Hosp Bern, Dept Urol, Inselspital, Bern, Switzerland
[15] Clin Univ St Luc, Dept Urol, Brussels, Belgium
[16] Netherlands Canc Inst, Dept Urol, Amsterdam, Netherlands
[17] Inst Paoli Calmettes Canc Ctr, Dept Urol, Marseille, France
来源
FRONTIERS IN ONCOLOGY | 2020年 / 10卷
关键词
prostate; prostate cancer; EMPACT; risk stratification; high risk prostate cancer;
D O I
10.3389/fonc.2020.00246
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cancer-specific survival (CSS) within high-risk non-metastatic prostate cancer varies dramatically. It is likely that within this heterogenous population there are subgroup(s) at extraordinary risk, burdened with an exaptational poor prognosis. Establishing the characteristics of these group(s) would have significant clinical implications since high quality preoperative risk stratification remains the cornerstone of therapeutic decision making to date. Objective: To stratify high-risk prostate cancer based on preoperative characteristics and evaluate cancer specific survival after radical prostatectomy. Method: The EMPaCT multi-center database offers an international population of non-metastatic high-risk prostate cancer. Preoperative characteristics such as age, biopsy Gleason score, PSA and clinical stage were subcategorized. A multivariate analysis was performed using predictors showing significant survival heterogeneity after stratification, as observed by a univariate analysis. Based upon the hazard ratios of this multivariate analysis, a proportional score system was created. The most ideal group distribution was evaluated trough different score cut-off's. The predictive value was tested by the herald C index. Results: An overall 5-years CSS of 94% was noted within the entire high-risk cohort (n = 4,879). Except for age, all preoperative risk factors showed a significantly differing CSS. Multivariate analysis indicated, T4 stage as being the strongest predictor of CSS (HR: 3.31), followed by ISUP grade 5 group (HR 3,05). A score system was created by doubling the hazard ratios of this multivariate analysis and rounding off to the nearest complete number. Multivariate analysis suggested 0, 4, 8, and 12 pts as being the most optimal group distribution (p-value: 0.0015). Five-years CSS of these groups were 97, 93, 87, and 70%, respectively. The calculated Herald C-index of the model was 0.77. Conclusion: An easy-to-use pre-operative model for risk stratification of newly diagnosed high-risk prostate cancer is presented. The heterogeneous CSS of high-risk non-metastatic prostate cancer after radical prostatectomy is illustrated. The model is clinically accessible through an online calculator, presenting cancer specific survival based on individualized patient characteristics.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Genomics and risk stratification in high-risk prostate cancer
    Bashir Al Hussein Al Awamlh
    Jonathan E. Shoag
    [J]. Nature Reviews Urology, 2019, 16 : 641 - 642
  • [2] Genomics and risk stratification in high-risk prostate cancer
    Al Awamlh, Bashir Al Hussein
    Shoag, Jonathan E.
    [J]. NATURE REVIEWS UROLOGY, 2019, 16 (11) : 641 - 642
  • [3] High-risk prostate cancer is worth further risk stratification
    Maffezzini, Massimo
    [J]. EUROPEAN UROLOGY, 2008, 53 (05) : 872 - 873
  • [4] Risk-stratification system for preoperative evaluation
    Wang, Peng-Hui
    Liu, Chia-Hao
    Yang, Szu-Ting
    [J]. JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2023, 86 (03) : 259 - 261
  • [5] Should PNI be included for risk-stratification of prostate cancer?
    Lee, I. H.
    Wei, J. T.
    Shah, R.
    Wojno, K.
    Sandler, H.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S205 - S206
  • [6] Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer
    Xiang, Michael
    Ma, Ting Martin
    Savjani, Ricky
    Pollom, Erqi L.
    Karnes, R. Jeffrey
    Grogan, Tristan
    Wong, Jessica K.
    Motterle, Giovanni
    Tosoian, Jeffrey J.
    Trock, Bruce J.
    Klein, Eric A.
    Stish, Bradley J.
    Dess, Robert T.
    Spratt, Daniel E.
    Pilar, Avinash
    Reddy, Chandana
    Levin-Epstein, Rebecca
    Wedde, Trude B.
    Lilleby, Wolfgang A.
    Fiano, Ryan
    Merrick, Gregory S.
    Stock, Richard G.
    Demanes, D. Jeffrey
    Moran, Brian J.
    Huland, Hartwig
    Tran, Phuoc T.
    Martin, Santiago
    Martinez-Monge, Rafael
    Krauss, Daniel J.
    Abu-Isa, Eyad I.
    Alam, Ridwan
    Schwen, Zeyad
    Pisansky, Thomas M.
    Choo, C. Richard
    Song, Daniel Y.
    Greco, Stephen
    Deville, Curtiland
    McNutt, Todd
    DeWeese, Theodore L.
    Ross, Ashley E.
    Ciezki, Jay P.
    Boutros, Paul C.
    Nickols, Nicholas G.
    Bhat, Prashant
    Shabsovich, David
    Juarez, Jesus E.
    Chong, Natalie
    Kupelian, Patrick A.
    Rettig, Matthew B.
    Zaorsky, Nicholas G.
    [J]. JAMA NETWORK OPEN, 2021, 4 (12) : E2138550
  • [7] TARGETED CANCER CORE LENGTH AND RISK-STRATIFICATION OF PROSTATE CANCER
    Simopoulos, Demetrios
    Sisk, Anthony
    Priester, Alan
    Kwan, Lorna
    Reiter, Robert
    Marks, Leonard
    [J]. JOURNAL OF UROLOGY, 2018, 199 (04): : E899 - E900
  • [8] Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer
    Riu Hamada
    Jun Nakashima
    Makoto Ohori
    Yoshio Ohno
    Osamu Komori
    Kunihiro Yoshioka
    Masaaki Tachibana
    [J]. International Journal of Clinical Oncology, 2016, 21 : 595 - 600
  • [9] Re: Performance of a Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography-derived Risk-stratification Tool for High-risk and Very High-risk Prostate Cancer
    Bjartell, Anders
    [J]. EUROPEAN UROLOGY, 2022, 82 (01) : 145 - 146
  • [10] Erratum to: Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer
    Riu Hamada
    Jun Nakashima
    Makoto Ohori
    Yoshio Ohno
    Osamu Komori
    Kunihiko Yoshioka
    Masaaki Tachibana
    [J]. International Journal of Clinical Oncology, 2016, 21 : 601 - 601